此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

The Effects of Losartan on Social Reward

2020年10月21日 更新者：Benjamin Becker、University of Electronic Science and Technology of China

Losartan Effects on the Social Reward in Humans

The aim of the study is to investigate the effect of losartan (50mg, single dose) on social reward

研究概览

地位

未知

条件

干预/治疗

详细说明

In a double-blind, between-subject, placebo-controlled design the effects of a single dose of losartan (50mg) on social reward in healthy participants will be examined. 90 minutes after subjects administrate 50mg losartan or placebo, participants will undergo a social incentive delay task. Neural activity will be assessed by the acquisition of functional magnetic resonance imaging (fMRI) data.

研究类型

介入性

注册 (预期的)

90

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 中国
    • Sichuan
      • Chengdu、Sichuan、中国、611731
        • 招聘中
        • University of Electronic Science and Technology of China
        • 接触：

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 30年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Healthy subjects without past or current psychiatric or neurological disorders

Exclusion Criteria:

  • history of head injury
  • medical or psychiatric illness
  • hypertension

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：基础科学
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的：氯沙坦组
药物：氯沙坦
药品：Losartan
administration of losartan (50 mg) (oral)
其他名称：
  • 科素亚口服片
安慰剂比较：安慰剂组
药物：安慰剂口服片剂
药品：安慰剂口服片剂
服用安慰剂（口服）

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Losartan effects on neural activity as assessed by blood oxygenation dependent (BOLD) fMRI during the anticipation of social feedback.
大体时间：90 minutes to 105 minutes after treatment
The social incentive delay task provides subjects with trial-wise feedback on their performance (as assessed by reaction time). Neural activity will be measured by functional magnetic resonance imaging (fMRI). To examine effects of treatment during the anticipation of social feedback fMRI-based neural indices during the anticipation period will be compared between the losartan and the placebo treated group using a Generalized Linear Model approach. The analysis will focus on brain systems that play an important role in the anticipation of reward and punishment (prefrontal cortex and subcortical regions, including the striatum)
90 minutes to 105 minutes after treatment
Losartan effects on neural activity as assessed by blood oxygenation dependent (BOLD) fMRI during the consummation of social feedback.
大体时间：90 minutes to 105 minutes after treatment
The social incentive delay task provides subjects with trial-wise feedback on their performance (as assessed by reaction time). Following each trial the feedback will be indicated by positive and negative social stimuli. Neural activity will be measured by functional magnetic resonance imaging (fMRI). To examine effects of treatment during the consummation of social feedback fMRI-based neural indices during the presentation of the feedback will be compared between the losartan and the placebo treated group using a Generalized Linear Model approach. The analysis will focus on brain systems that play an important role in reward and punishment (prefrontal cortex and subcortical regions, including the striatum)
90 minutes to 105 minutes after treatment

次要结果测量

结果测量
措施说明
大体时间
Effects of Losartan on arousal ratings of the stimuli presented during the fMRI-paradigm as assessed by 1-9 Likert scales
大体时间：150 minutes to 160 minutes after treatment
Following the fMRI assessment participants will be asked to rate the arousal of the stimuli presented during fMRI. Arousal will be assessed on 1-9 Likert rating scales. To examine effects of treatment on arousal ratings the losartan and placebo groups will be compared using Generalized Linear Model approach.
150 minutes to 160 minutes after treatment
Effects of Losartan on valence ratings of the stimuli presented during the fMRI-paradigm as assessed by 1-9 Likert scales
大体时间：150 minutes to 160 minutes after treatment
Following the fMRI assessment participants will be asked to rate the valence of the stimuli presented during fMRI. Valence will be assessed on 1-9 Likert rating scales. To examine effects of treatment on valence ratings the losartan and placebo groups will be compared using Generalized Linear Model approach.
150 minutes to 160 minutes after treatment
Effects of Losartan on intensity ratings of the stimuli presented during the fMRI-paradigm as assessed by 1-9 Likert scales
大体时间：150 minutes to 160 minutes after treatment
Following the fMRI assessment participants will be asked to rate the intensity of the stimuli presented during fMRI. Intensity will be assessed on 1-9 Likert rating scales. To examine effects of treatment on intensity ratings the losartan and placebo groups will be compared using Generalized Linear Model approach.
150 minutes to 160 minutes after treatment
Effects of Losartan on likeability ratings of the stimuli presented during the fMRI-paradigm as assessed by 1-9 Likert scales
大体时间：150 minutes to 160 minutes after treatment
Following the fMRI assessment participants will be asked to rate the likeability of the stimuli presented during fMRI. Likeability will be assessed on 1-9 Likert rating scales. To examine effects of treatment on likeability ratings the losartan and placebo groups will be compared using Generalized Linear Model approach.
150 minutes to 160 minutes after treatment
Effects of Losartan on dislikeability ratings of the stimuli presented during the fMRI-paradigm as assessed by 1-9 Likert scales
大体时间：150 minutes to 160 minutes after treatment
Following the fMRI assessment participants will be asked to rate the dislikeability of the stimuli presented during fMRI. Dislikeability will be assessed on 1-9 Likert rating scales. To examine effects of treatment on dislikeability ratings the losartan and placebo groups will be compared using Generalized Linear Model approach.
150 minutes to 160 minutes after treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

University of Electronic Science and Technology of China

调查人员

  • 首席研究员：Benjamin Becker, PhD、University of Electronic Science and Technology of China

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年10月10日

初级完成 (预期的)

2021年12月31日

研究完成 (预期的)

2022年3月31日

研究注册日期

首次提交

2020年10月9日

首先提交符合 QC 标准的

2020年10月21日

首次发布 (实际的)

2020年10月27日

研究记录更新

最后更新发布 (实际的)

2020年10月27日

上次提交的符合 QC 标准的更新

2020年10月21日

最后验证

2020年10月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • UESTC-neuSCAN-72

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅